hC Bioscience to Present at Locust Walk RNA Innovation Conference
Cambridge, MA – May 2, 20223 -- hC Bioscience (Private) announced that Leslie Williams, president and CEO, will deliver a presentation on the science behind tRNA-based therapies and the company's therapeutic programs at the Locust Walk RNA Innovation Conference on Tuesday, May 9, 2023, at 11:00 a.m. ET.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- hC Bioscience to present at the Locust Walk RNA Innovation Conference.
- The presentation will highlight the science behind tRNA-based therapies and the company's therapeutic programs.
- Conference attendees can view the presentation Tuesday, May 9, 2023, at 11:00 a.m. ET.
Click image above to view full announcement.
About hC Bioscience, Inc.
hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics to target protein dysfunction. hC Bioscience’s innovative approach to precision protein editing has the potential to treat genetically defined conditions, which account for 10-15% of all human disease. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.
To learn more, visit hCBioscience.com
hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics to target protein dysfunction. hC Bioscience’s innovative approach to precision protein editing has the potential to treat genetically defined conditions, which account for 10-15% of all human disease. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.
To learn more, visit hCBioscience.com
Contacts:
Savannah Beaver
(617) 804-0366
[email protected]
Source: hC Bioscience
Distributed by: Reportable, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mayfair Gold Schedules Annual General and Special Meeting of Shareholders in Response to Shareholder Requisition
- HOME BANCORP, INC. ANNOUNCES 2024 FIRST QUARTER RESULTS AND DECLARES QUARTERLY DIVIDEND
- Fidelity D & D Bancorp, Inc. Second Quarter 2024 Dividend
Create E-mail Alert Related Categories
Press Releases, ReportableSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!